StreetAlpha.app
Home › Stocks › MIST

Milestone Pharmaceuticals Inc. (MIST)

Healthcare
$0.42
▲ +15.12%
LAST CLOSE · NOV 17

Milestone Pharmaceuticals sells CARDAMYST, a nasal spray for treating a rapid heartbeat condition called PSVT. It last closed at $0.42 on Nov 17, up 15.12% on the day. MIST last reported earnings on Fri, Nov 13, 2026. The average 12-month price target from 4 analysts is $4.25 (+911.4% from the last close), with a high of $6.00 and a low of $3.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).

AI Auto Pilots
Is MIST in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$97.9M
EPS (diluted)
−$0.74
Free cash flow
−$77.1M
Valuation
Market cap
$52.3M
124.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$144.5M
At Sep 30
Debt
$60.2M
At Sep 30
Shareholder equity
−$6.2M
Shares outstanding
124.5M
At Nov 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$42.9M−$42.9MFY2021FY2022: −$58.4M−$58.4MFY2022FY2023: −$59.7M−$59.7MFY2023FY2024: −$41.5M−$41.5MFY2024FY2025: −$63.1M−$63.1MFY2025

From MIST's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Last report
Nov 13
2026 · Before the open (BMO)
Reported EPS
-$0.18
vs -$0.20 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±38.7%
Priced in before that report
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on MIST in the past 90 days
Average 12-month target
$4.25
▲ 911.4% upside

Based on 4 analysts who set a price target on MIST in the past 90 days. The average target is $4.25, with a high of $6.00 and a low of $3.00, compared with the last close of $0.42.

Low $3.00Avg $4.25High $6.00
Blue marker: last close $0.42
Highest target$6.00
Average target$4.25
Lowest target$3.00
Latest rating changes
TD CowenMaintained
Nov 16Buy$5
Piper SandlerMaintained
Nov 16Buy$3
HC Wainwright & Co.Maintained
Nov 16Buy$6
Cantor FitzgeraldInitiated
Aug 20Buy$3
DateFirmActionRatingPrice target
Nov 16TD CowenMaintainedBuy$5
Nov 16Piper SandlerMaintainedBuy$3
Nov 16HC Wainwright & Co.MaintainedBuy$6
Aug 20Cantor FitzgeraldInitiatedBuy$3
Loading…

Technical Analysis

MIST · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 60% below its 20 day and 84% below its 50 day average. It is 208% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the Pivot at $0.42, and the nearest resistance the Pivot R1 at $0.46.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 19.3%/day
Key levels
$3.0652 week high+628.6%
$1.29200 day average+207.1%
$0.98100 day average+133.3%
$0.81Swing high (Oct 12)+92.9%
$0.7750 day average+83.3%
$0.6720 day average+59.5%
$0.46Pivot R1+9.5%
$0.42Pivot+0.0%
$0.42Last close
$0.38Pivot S1−9.5%
$0.3652 week low−14.3%
Indicators
RSI (14)29.90Oversold below 30Oversold
MACD-0.08Below its signal lineBearish
Stochastic6.2Near the bottom of its rangeOversold
ADX (14)28.6Trending down
Williams %R-87.9Oversold below −80, overbought above −20Oversold
CCI (20)-246.1Oversold below −100, overbought above 100Oversold
Rate of change−44.7%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 19.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for MIST

What happened before

See how MIST did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow MIST usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MIST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in MIST in the last 90 days.

Loading…

See today’s whale options flow across the market →

MIST Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●27 buying vs 28 selling
  • ●Held by funds -0.4 pts
  • ▼Funds holding -4
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7478−5.1%
In funds' top 10330.0%
Held by funds40.5%40.8%−0.4 pts
New / increased12 / 156 / 23−6.9%
Reduced / sold out15 / 1323 / 13−22.2%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MIST institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MIST is in one of them and how their past MIST trades turned out.

MIST in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MIST in an article yet. Here's the latest on the wider market.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals is a biopharmaceutical company based in Montreal, Quebec, Canada, that develops heart medicines. Its main product is CARDAMYST, a nasal spray containing etripamil that patients can use themselves to stop an episode of PSVT, a condition that causes the heart to suddenly beat too fast. The product is sold in the United States through retail pharmacies, and the company is developing etripamil for atrial fibrillation as well. Its customers are patients and the doctors, mainly cardiologists, who prescribe its medicines.

Headquarters
Montreal, Quebec, Canada